[{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/failures.ts","type":"changed","fields":[{"field":"tldr","before":"\"Sanofi's ADC against the classic CEA tumour marker, stopped for futility in lung cancer in 2023.\"","after":"\"Tusamitamab ravtansine was Sanofi's ADC against the classic CEA tumour marker, stopped for futility in lung cancer in 2023.\""}]},{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/","commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, isotope tracker, Cli","file":"src/data/failures.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"code"},{"field":"modality"},{"field":"asOf"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"payload"},{"field":"linker"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"tags"},{"field":"links"}]}]